发明名称 RTEF-1 variants and uses thereof
摘要 Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.
申请公布号 US8785385(B2) 申请公布日期 2014.07.22
申请号 US201113089687 申请日期 2011.04.19
申请人 Research Development Foundation;Oregon Health & Science University 发明人 Stout J. Timothy;Appukuttan Binoy;McFarland Trevor;Dye Anna
分类号 C07K14/435;A61K38/00;A61K38/16;A61K38/17 主分类号 C07K14/435
代理机构 Parker Highlander PLLC 代理人 Parker Highlander PLLC
主权项 1. An isolated variant RTEF-1 polypeptide that reduces VEGF promoter activity comprising an amino acid sequence that is at least 95% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, and 12, further wherein said polypeptide does not include an amino acid sequence consisting of amino acids 1-16 of SEQ ID NO:8.
地址 Carson City NV US